Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 577

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 577
---
 during the year ended December 31, 2023, and lower stock compensation expense related to time-based restricted stock units that vested in February 2023. Other R&D operating expenses for the year ended December 31, 2023 included $1.7 million related to the agreement with Patheon for forecasted manufacturing commitments that are no longer needed due to the reduced demand expectations of KORSUVA in the United States, as well as increased payroll-related costs as compared to the prior period. Other R&D operating expenses for the year ended December 31, 2022 included the recognition of the $5.0 million milestone payment due to Enteris. The following table summarizes our R&D expenses by product candidate for the years ended December 31, 2023 and 2022:

| ​                                                                 
 ​                                                                 | ​ 
 ​ | ​ 
 ​ | Year Ended December 31,     
 2023                        |   |         |   |   |   |          | ​ | ​ | 2022 |   |        |   |   |   |          | ​ 
 ​ |
|:------------------------------------------------------------------|:--|:--|:----------------------------|:--|--------:|:--|:--|:--|:---------|:--|:--|:-----|:--|-------:|:--|:--|:--|:---------|:--|
| ​                                                                 | ​ | ​ | Dollar amounts in thousands |   |         |   |   |   |          |   |   |      |   |        |   |   |   |          | ​ |
| ​                                                                 | ​ | ​ | ​                           | ​ |       ​ | ​ | ​ | ​ | % change | ​ | ​ | ​    | ​ |      ​ | ​ | ​ | ​ | % change | ​ |
| External research and development expenses:                       | ​ | ​ | ​                           | ​ |       ​ | ​ | ​ | ​ | ​        | ​ | ​ | ​    | ​ |      ​ | ​ | ​ | ​ | ​        | ​ |
| KORSUVA (difelikefalin) injection – Pruritus                      | ​ | ​ | ​                           | $ |       — | ​ | ​ | ​ | (100)%   | ​ | ​ | ​    | $ |  6,692 | ​ | ​ | ​ | (31)%    | ​ |
| Oral difelike